- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04248192
Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)
A Study to Evaluate the Safety, Immunologic, and Virologic RESponses of Donor Derived (DD) HIV-Specific T-cells (HST) With Non-escaped Epitope Targeting (NEETs) in HIV-Infected Individuals on Antiretroviral Therapy Following Allogeneic Bone Marrow Transplantation (alloRESIST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Richard Ambinder, MD, PhD
- Phone Number: 410 955-8839
- Email: rambind1@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Recruiting
- Johns Hopkins University(Jhu)
-
Contact:
- Laura Clark, MS PA-C
- Phone Number: 410-502-5396
- Email: lclark53@jhmi.edu
-
Principal Investigator:
- Richard Ambinder, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participant Inclusion Criteria at Screening:
- Age ≥18 years.
- Confirmation of HIV-1 infection. Any licensed ELISA test kit which is confirmed by Western blot or Multispot HIV-1/HIV-2 assay prior to screening. HIV culture, HIV antigen, plasma HIV RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test.
- On effective antiretroviral therapy.
- Ability and willingness of participant to continue and be compliant with ART throughout the study.
- Hematologic malignancy that qualifies for standard of care alloBMT according to JHU criteria.
- Potential participant must have adequate organ function for standard of care alloBMT according to JHU criteria.
- No active HCV infection. (If seropositive, participant must have no measureable HCV RNA within 30 days of enrollment).
- No active HBV infection (If seropositive, participant must have no measureable HBV DNA or HBsAg+ within 30 days of enrollment).
- Ability and willingness of participant to give written informed consent.
- Ability and willingness to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.
- Ability and willingness to provide adequate locator information and contact information for at least 2 adults who can reach the participant within 24 hours
Participant Inclusion Criteria for DD HST-NEETs Infusion:
- Karnofsky score of ≥ 70.
- ANC ≥ 250/µL.
- Bilirubin ≤ 2x upper limit normal or direct bilirubin normal.
- AST ≤ 3x upper limit normal.
- Serum creatinine ≤ 2x upper limit normal.
- Hgb ≥ 7.0 g/dL.
- Pulse oximetry of > 90% on room air.
- Negative pregnancy test in female participants if applicable (childbearing potential).
- Written informed consent signed by participant or guardian.
- Steroids less or equal to 0.5 mg/kg/day prednisone.
Donor Inclusion Criteria for Procurement for DD HST-NEETS Manufacturing:
- Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) hematopoietic cell transplants who have fulfilled eligibility for and consented to stem cell donation as per JHU standard operating procedures.
- Donor must be in good health based on institutional guidelines.
- Female donors of childbearing age must have a negative pregnancy test and must not be lactating.
- It is understood that medical clearance from the donor will be sought within the timeline per the National Marrow Donor Program (NMDP) rules.
- The hematopoietic cell donor will have already been selected by the JHU BMT Donor Selection Committee.
- Donor or parent/guardian capable of providing informed consent
Exclusion Criteria:
Participant Exclusion Criteria DD HST-NEETs Infusion:
- Participants receiving ATG, or Campath or other immunosuppressive T-cell monoclonal antibodies within 28 days.
- Participants with uncontrolled infections. For bacterial infections, participants must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections participants must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.
- Participants who have received donor lymphocyte infusion (DLI) within 28 days.
- Active and uncontrolled relapse of malignancy.
- Participants with active acute GVHD grades II-IV
- Participants with bronchiolitis obliterans syndrome or serositis
- Any licensed or experimental non-HIV vaccination (e.g., hepatitis B, pneumococcal polysaccharide) within 28 days prior to study entry.
- Inability to comply with study requirements, which could impact study integrity and/or safety.
Donor Exclusion Criteria for Procurement for DD HST-NEETs Manufacturing:
• Donor exclusion criteria will be followed as per institution standard operating procedures (SOPs).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Donor Derived HIV-Specific T-cells (DD HST-NEETs)
Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
|
HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy.
Participants and donors will be screened for eligibility.
Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs.
Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Any ≥ Grade 3 Adverse Events (as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0)
Time Frame: 45 days
|
Any ≥ Grade 3 Adverse Events will be measured by number of participants who experience Dose Limiting Toxicity which is attributable to the DD HST-NEETS administration.
|
45 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The feasibility of manufacturing of DD HST-NEETs
Time Frame: 3 years
|
Feasibility of the manufacturing process will be measured by generation of the cells in 4 or more donors (i.e., a rate of 50% of more).
|
3 years
|
The HIV reservoir measurements
Time Frame: 3 years
|
Summarize the HIV reservoir measurements over the pre-BMT, pre-DD HST-NEETs infusion, post-infusion period to assess any change in the HIV reservoir following infusion.
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Keller, MD, CNMC
- Principal Investigator: Richard Ambinder, MD, PhD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Pro00012451
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-Infected Individuals
-
University Hospital, Strasbourg, FranceNot yet recruitingInformed Consent | HIV Infected Individuals
-
Imperial College LondonHammersmith Hospitals NHS Trust; Johrei AssociationCompletedHIV Infected IndividualsUnited Kingdom
-
Azienda Ospedaliera di PerugiaCompleted
-
The HIV Netherlands Australia Thailand Research...Chulalongkorn University; Queen Sirikit National Institute of Child Health; Srinagarind... and other collaboratorsCompletedHIV-infected ChildrenThailand
-
University of Alabama at BirminghamNational Institute of Allergy and Infectious Diseases (NIAID)WithdrawnHIV InfectedUnited States
-
The HIV Netherlands Australia Thailand Research...Chulalongkorn University; Bamrasnaradura Infectious Diseases InstituteCompleted
-
Hospices Civils de LyonCompleted
-
WestatEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPNC Vaccine | HIV-infected Pregnant WomenBrazil
-
ANRS, Emerging Infectious DiseasesCompleted
-
Università Vita-Salute San RaffaeleIRCCS San Raffaele; Merck Sharp & Dohme LLCUnknownHIV-1 Infected Patients | Fold-change Resistance | Resistance MutationsItaly
Clinical Trials on DD HST-NEETs
-
Catherine BollardNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsRecruitingHIV Associated LymphomaUnited States
-
Catherine BollardActive, not recruitingHIV InfectionsUnited States
-
Home Skinovations Ltd.Completed
-
Fortuderm Ltd.UnknownPsoriasis VulgarisIsrael
-
Northwell HealthCompletedVenous Thromboembolism | Arterial ThromboembolismUnited States
-
Scripps Whittier Diabetes InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Covid19United States
-
CHABiotech CO., LtdSeoul CRO Co., Ltd.CompletedChronic Low-back Pain | Disc DegenerationKorea, Republic of
-
HistogenCompleted
-
Cambridge Health AllianceSpaulding Rehabilitation Hospital; Korea Advanced Institute of Science and...Not yet recruiting